KR102357312B1 - Cd20 결합 분자 및 그의 용도 - Google Patents

Cd20 결합 분자 및 그의 용도 Download PDF

Info

Publication number
KR102357312B1
KR102357312B1 KR1020177027838A KR20177027838A KR102357312B1 KR 102357312 B1 KR102357312 B1 KR 102357312B1 KR 1020177027838 A KR1020177027838 A KR 1020177027838A KR 20177027838 A KR20177027838 A KR 20177027838A KR 102357312 B1 KR102357312 B1 KR 102357312B1
Authority
KR
South Korea
Prior art keywords
ser
delete delete
thr
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177027838A
Other languages
English (en)
Korean (ko)
Other versions
KR20170122258A (ko
Inventor
브루스 케이트
오마르 두라마드
비어트리스 티엔-이 왕
라메쉬 발리가
펜 장
Original Assignee
아이쥐엠 바이오사이언스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이쥐엠 바이오사이언스 인코포레이티드 filed Critical 아이쥐엠 바이오사이언스 인코포레이티드
Priority to KR1020227002813A priority Critical patent/KR20220018081A/ko
Publication of KR20170122258A publication Critical patent/KR20170122258A/ko
Application granted granted Critical
Publication of KR102357312B1 publication Critical patent/KR102357312B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020177027838A 2015-03-04 2016-03-04 Cd20 결합 분자 및 그의 용도 Active KR102357312B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227002813A KR20220018081A (ko) 2015-03-04 2016-03-04 Cd20 결합 분자 및 그의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128284P 2015-03-04 2015-03-04
US62/128,284 2015-03-04
PCT/US2016/020920 WO2016141303A2 (en) 2015-03-04 2016-03-04 Cd20 binding molecules and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227002813A Division KR20220018081A (ko) 2015-03-04 2016-03-04 Cd20 결합 분자 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20170122258A KR20170122258A (ko) 2017-11-03
KR102357312B1 true KR102357312B1 (ko) 2022-02-03

Family

ID=56849117

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020177027838A Active KR102357312B1 (ko) 2015-03-04 2016-03-04 Cd20 결합 분자 및 그의 용도
KR1020247029325A Ceased KR20240135877A (ko) 2015-03-04 2016-03-04 Cd20 결합 분자 및 그의 용도
KR1020227002813A Ceased KR20220018081A (ko) 2015-03-04 2016-03-04 Cd20 결합 분자 및 그의 용도
KR1020237028892A Ceased KR20230130148A (ko) 2015-03-04 2016-03-04 Cd20 결합 분자 및 그의 용도

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020247029325A Ceased KR20240135877A (ko) 2015-03-04 2016-03-04 Cd20 결합 분자 및 그의 용도
KR1020227002813A Ceased KR20220018081A (ko) 2015-03-04 2016-03-04 Cd20 결합 분자 및 그의 용도
KR1020237028892A Ceased KR20230130148A (ko) 2015-03-04 2016-03-04 Cd20 결합 분자 및 그의 용도

Country Status (18)

Country Link
US (2) US10787520B2 (enExample)
EP (2) EP3957738A1 (enExample)
JP (3) JP6793655B2 (enExample)
KR (4) KR102357312B1 (enExample)
CN (2) CN115093479A (enExample)
AU (3) AU2016226060B2 (enExample)
BR (1) BR112017018941B8 (enExample)
CA (1) CA2978324A1 (enExample)
DK (1) DK3265575T3 (enExample)
ES (1) ES2874558T3 (enExample)
HU (1) HUE054642T2 (enExample)
IL (2) IL297997A (enExample)
NZ (1) NZ762365A (enExample)
PL (1) PL3265575T3 (enExample)
PT (1) PT3265575T (enExample)
SG (2) SG11201707144VA (enExample)
SI (1) SI3265575T1 (enExample)
WO (1) WO2016141303A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105722855B (zh) 2013-09-05 2021-04-23 Igm生物科学股份有限公司 恒定链经修饰的双特异性五价和六价Ig-M抗体
EP3575312A1 (en) 2014-01-27 2019-12-04 Molecular Templates, Inc. De-immunized shiga toxin a subunit effector polypeptides for applications in mammals
KR102378289B1 (ko) 2014-02-10 2022-03-23 아이쥐엠 바이오사이언스 인코포레이티드 IgA 다중-특이적 결합 분자
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
CN112759650B (zh) 2014-04-03 2024-10-01 Igm生物科学股份有限公司 修饰的j链
CA2947048C (en) 2014-06-11 2023-10-17 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
CA2972990A1 (en) 2015-01-20 2016-07-28 Beatrice Tien-Yi WANG Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CN108064247B (zh) 2015-02-05 2022-06-03 分子模板公司 包含志贺毒素a亚基效应物区域的多价cd20结合分子及其富集组合物
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CN107847591B (zh) 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
WO2017059387A1 (en) * 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain
PL3355913T3 (pl) * 2015-09-30 2025-02-17 Igm Biosciences, Inc. Cząsteczki wiążące ze zmodyfikowanym łańcuchem j
DK3455257T3 (da) 2016-05-09 2021-11-01 Igm Biosciences Inc Anti-pd-l1-antistoffer
EP3551645A1 (en) 2016-12-07 2019-10-16 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
JP7082424B2 (ja) 2017-01-25 2022-06-08 モレキュラー テンプレーツ,インク. 脱免疫化された志賀毒素aサブユニットエフェクター及びcd8+t細胞エピトープを含む細胞標的化分子
KR102696143B1 (ko) 2017-04-07 2024-08-21 아이쥐엠 바이오사이언스 인코포레이티드 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역
MX2020009069A (es) 2018-03-01 2020-10-08 Igm Biosciences Inc Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero.
MX2019009726A (es) 2018-04-17 2020-02-05 Molecular Templates Inc Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.
EP3870223A4 (en) * 2018-10-23 2022-08-24 IGM Biosciences, Inc. MULTIVALENT IGM AND IGA-FC BASED BINDING MOLECULES
CA3147291A1 (en) 2019-08-15 2021-02-18 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
WO2021055765A2 (en) * 2019-09-19 2021-03-25 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
EP4139362A2 (en) 2020-04-22 2023-03-01 IGM Biosciences Inc. Pd-1 agonist multimeric binding molecules
US20240002526A1 (en) * 2020-11-17 2024-01-04 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
CN112521508B (zh) * 2020-12-29 2021-08-03 郴州宾泽医学检验有限公司 一种cd20抗体及其治疗癌症的应用
EP4294829A4 (en) * 2021-02-17 2025-03-19 IGM Biosciences Inc. ANTI-CD123 BINDING MOLECULES AND THEIR USES
NL2030990B1 (en) * 2022-02-17 2023-09-01 Academisch Ziekenhuis Leiden T cell receptors directed against jchain and uses thereof
WO2024073700A2 (en) * 2022-09-30 2024-04-04 Igm Biosciences, Inc. Methods of treating autoimmune disorders using multimeric anti-cd20/anti-cd3 antibodies
WO2024148336A1 (en) * 2023-01-06 2024-07-11 Igm Biosciences, Inc. T cell costimulatory multimeric binding molecules and uses thereof
WO2025076144A1 (en) * 2023-10-03 2025-04-10 Atara Biotherapeutics, Inc. Bispecific cd19/cd20-targeted chimeric antigen receptors and uses thereof
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8719963D0 (en) 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
AU697387C (en) 1994-09-16 2006-03-02 Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 Polypeptides with Fc binding ability
US6808709B1 (en) 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
CA2276046A1 (en) * 1997-01-10 1998-07-16 Epicyte Pharmaceutical, Inc. Novel epithelial tissue targeting agent
US6045774A (en) 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
AU3655899A (en) 1998-04-20 1999-11-08 Regents Of The University Of California, The Modified immunoglobulin molecules and methods for use thereof
DE60042785D1 (de) 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
MXPA02010011A (es) * 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
DK1290027T3 (da) 2000-04-28 2010-01-18 Planet Biotechnology Inc Immunoadhæsin til forebyggelse af rhinovirusinfektion
US7947463B2 (en) 2000-05-10 2011-05-24 Signe Biopharma, Inc. Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050129616A1 (en) 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
AU2003208415B2 (en) 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
WO2003074567A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Internalizing anti-cd74 antibodies and methods of use
AU2003234736B2 (en) 2002-04-12 2008-09-25 E. R. Squibb & Sons, L.L.C. Methods of treatment using CTLA-4 antibodies
AU2003277087B2 (en) 2002-06-14 2008-07-31 Immunomedics, Inc. Humanized monoclonal antiboby hPAM4
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
EA021644B1 (ru) * 2002-10-17 2015-08-31 Генмаб А/С Человеческое моноклональное антитело против cd20 и его применение
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
WO2004104046A1 (en) 2003-05-23 2004-12-02 Crucell Holland B.V. Production of recombinant igm in per.c6 cells
ATE490787T1 (de) 2003-07-15 2010-12-15 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
EP1686137A4 (en) 2003-10-09 2009-10-28 Chugai Pharmaceutical Co Ltd PROCESS FOR STABILIZING PROTEIN SOLUTIONS
HRP20110187T1 (hr) 2003-10-16 2011-04-30 Micromet Ag Multispecifične deimunizirane tvari koje vežu cd3
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー/エスGenmab A/S Cd20に対するヒトモノクローナル抗体
AU2005304973A1 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
ES2829566T3 (es) 2005-03-03 2021-06-01 Immunomedics Inc Anticuerpos L243 humanizados
US8349332B2 (en) * 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
EP1891113A2 (en) * 2005-06-02 2008-02-27 AstraZeneca AB Antibodies directed to cd20 and uses thereof
DE602006015653D1 (de) * 2005-08-03 2010-09-02 Therapeutic Human Polyclonals Unterdrückung der b-zell apoptose in transgenen tieren die humanisierte immunglobulingene exprimieren
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN103242451B (zh) * 2005-12-16 2017-11-21 Ibc医药公司 基于免疫球蛋白的多价生物活性装配体
MX2008008046A (es) 2005-12-21 2009-03-04 Micromet Ag Moleculas de epha2-bite y usos de las mismas.
NZ596865A (en) 2006-06-12 2013-07-26 Emergent Product Dev Seattle Single-chain multivalent binding proteins with effector function
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
WO2008114011A2 (en) * 2007-03-19 2008-09-25 Medimmune Limited Fc polypeptide variants obtained by ribosome display methodology
US20100298223A1 (en) 2007-05-02 2010-11-25 Dietmar Rudolf Fries Fibrinogen for treatment of bleeding in trauma and platelet disorders
CN201229536Y (zh) 2008-07-03 2009-04-29 鸿富锦精密工业(深圳)有限公司 电脑机箱
US20120269830A1 (en) 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
AU2010343056A1 (en) 2009-12-29 2012-08-02 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
MX2012009321A (es) 2010-02-11 2012-11-21 Alexion Pharma Inc Metodos terapeuticos que utilizan anticuerpos anti-cd200.
AU2011318567B2 (en) 2010-10-19 2017-02-09 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
EP2791171A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
ES2735289T3 (es) 2012-02-08 2019-12-17 Igm Biosciences Inc Proteínas de unión a cdim y usos de las mismas
WO2013150138A1 (en) * 2012-04-05 2013-10-10 Gottfried Himmler Secretory immunoglobulin complex
BR112014025898A2 (pt) 2012-04-17 2017-11-07 Mayo Found Medical Education & Res anticorpos humanos e sequências de ligação específica, para uso em acidente vascular cerebral e isquemia ou condições isquêmicas
US20150175678A1 (en) 2012-06-15 2015-06-25 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
JP2015524821A (ja) * 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014124457A1 (en) 2013-02-11 2014-08-14 University Of Louisville Research Foundation, Inc. Methods for producing antibodies
US9487773B2 (en) 2013-03-01 2016-11-08 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Cell-based methods for coupling protein interactions and binding molecule selection
GB201311487D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
CN105722855B (zh) * 2013-09-05 2021-04-23 Igm生物科学股份有限公司 恒定链经修饰的双特异性五价和六价Ig-M抗体
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
BR112016015140A2 (pt) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
SG11201605691VA (en) 2014-01-16 2016-08-30 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
KR102378289B1 (ko) 2014-02-10 2022-03-23 아이쥐엠 바이오사이언스 인코포레이티드 IgA 다중-특이적 결합 분자
ES2770684T3 (es) 2014-03-14 2020-07-02 Novartis Ag Moléculas de anticuerpos contra LAG-3 y usos de los mismos
CN112759650B (zh) 2014-04-03 2024-10-01 Igm生物科学股份有限公司 修饰的j链
CA2972990A1 (en) 2015-01-20 2016-07-28 Beatrice Tien-Yi WANG Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CN107847591B (zh) 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
WO2017059387A1 (en) 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain
PL3355913T3 (pl) * 2015-09-30 2025-02-17 Igm Biosciences, Inc. Cząsteczki wiążące ze zmodyfikowanym łańcuchem j
DK3455257T3 (da) 2016-05-09 2021-11-01 Igm Biosciences Inc Anti-pd-l1-antistoffer
MX2019000796A (es) 2016-07-20 2019-06-03 Igm Biosciences Inc Moleculas multimericas de union a ox40 y usos de las mismas.
AU2017300647A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric GITR binding molecules and uses thereof
WO2018017763A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd40 binding molecules and uses thereof
EP3487298A4 (en) 2016-07-20 2020-03-11 IGM Biosciences, Inc. MULTIMERE CD137 / 4-1BB-BINDING MOLECULES AND USES THEREOF
KR102696143B1 (ko) 2017-04-07 2024-08-21 아이쥐엠 바이오사이언스 인코포레이티드 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역
CN111757941A (zh) 2018-02-26 2020-10-09 Igm生物科学股份有限公司 多聚体抗dr5结合分子与化学治疗剂联合用于治疗癌症的用途
MX2020009069A (es) 2018-03-01 2020-10-08 Igm Biosciences Inc Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero.
EP3870223A4 (en) 2018-10-23 2022-08-24 IGM Biosciences, Inc. MULTIVALENT IGM AND IGA-FC BASED BINDING MOLECULES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Haematologica, 97권, 11호, 1686-1694페이지(2012.11.)*
Science, 342권, 6141호, 88-91페이지(2013.07.05.)*

Also Published As

Publication number Publication date
BR112017018941A2 (en) 2018-04-17
US20190100597A1 (en) 2019-04-04
SG10202109717TA (en) 2021-10-28
CA2978324A1 (en) 2016-09-09
KR20220018081A (ko) 2022-02-14
PT3265575T (pt) 2021-06-16
EP3957738A1 (en) 2022-02-23
JP2023099206A (ja) 2023-07-11
BR112017018941A8 (pt) 2018-06-12
IL254223B1 (en) 2023-01-01
EP3265575A4 (en) 2018-08-08
KR20240135877A (ko) 2024-09-12
SG11201707144VA (en) 2017-09-28
PL3265575T3 (pl) 2021-11-29
CN115093479A (zh) 2022-09-23
AU2016226060A1 (en) 2017-10-12
JP6793655B2 (ja) 2020-12-02
JP2021036885A (ja) 2021-03-11
BR112017018941B1 (pt) 2022-03-03
BR112017018941B8 (pt) 2023-01-10
NZ762365A (en) 2024-11-29
CN107532188A (zh) 2018-01-02
US20210032357A1 (en) 2021-02-04
EP3265575B1 (en) 2021-04-21
IL254223B2 (en) 2023-05-01
IL254223A (en) 2017-10-31
WO2016141303A3 (en) 2016-11-03
US10787520B2 (en) 2020-09-29
JP2018508214A (ja) 2018-03-29
AU2020202667A1 (en) 2020-05-14
HUE054642T2 (hu) 2021-09-28
KR20230130148A (ko) 2023-09-11
CN107532188B (zh) 2022-05-10
KR20170122258A (ko) 2017-11-03
NZ735607A (en) 2024-01-26
WO2016141303A2 (en) 2016-09-09
EP3265575A2 (en) 2018-01-10
IL297997A (en) 2023-01-01
AU2023203119A1 (en) 2023-06-15
ES2874558T3 (es) 2021-11-05
DK3265575T3 (da) 2021-05-31
SI3265575T1 (sl) 2021-08-31
AU2016226060B2 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
KR102357312B1 (ko) Cd20 결합 분자 및 그의 용도
JP7499813B2 (ja) 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
JP7595696B2 (ja) Cd3抗原結合性断片及びその使用
CN108136001B (zh) 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
KR102577551B1 (ko) TGFβ 항체, 방법 및 용도
KR20220050971A (ko) 신규 항-cd39 항체
JP2023550832A (ja) CD39およびTGFβを標的とする新規のコンジュゲート分子
KR20210143096A (ko) Cd22에 특이적인 항체 및 이의 용도
KR20230146032A (ko) Tgf-b 신호전달을 조절하기 위한 세포 치료 조성물 및 방법
CN115521379B (zh) Pd-1抗体及其用途
HK1241931B (en) Cd20 binding molecules and uses thereof
HK40016537B (zh) 抗pd-1抗体及其用途
HK1253276B (en) Treatment of cancer using inhibitors of tgf-beta and pd-1

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170928

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20180321

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PN2301 Change of applicant

Patent event date: 20181022

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200326

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210527

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20211025

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220125

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220125

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220126

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20241224

Start annual number: 4

End annual number: 4